
|Videos|October 29, 2021
Penile curvature improvement in Peyronie's disease assessed in post hoc analysis of IMPRESS trials
Author(s)Urology Times staff
“The goal of this study was to look at that original phase 3 trial data [from 2013] and see if we could identify how much change in curvature patients were achieving with each of those 2 injections,” says Matthew J. Ziegelmann, MD.
Advertisement
In this video, Matthew J. Ziegelmann, MD, discusses the background of the study, “Collagenase clostridium histolyticum treatment for Peyronie’s disease: analysis of outcomes and cumulative benefits after each injection cycle,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Ziegelmann is a urologist at the Mayo Clinic, Rochester, Minnesota.
Advertisement
Latest CME
Advertisement
Advertisement











